Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

News SummaryMost relevantAll newsSector newsTweets 

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

share with twitter share with LinkedIn share with facebook
share via e-mail
04/26/2012 | 07:01pm CEST
   By Peter Loftus 

Drug maker Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas.

Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries."

The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing.

Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA.

U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement.

Last year, Johnson & Johnson (>> Johnson & Johnson) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein.

Other drug makers--including Pfizer Inc. (>> Pfizer Inc.), Merck & Co. (>> Merck & Co., Inc.) and Eli Lilly & Co. (>> Eli Lilly & Co.)--also have been the subjects of federal inquiries regarding the FCPA.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
07:11p BRISTOL MYERS SQUIBB : Reduces Environmental Impact Across the Globe
07:31a BRISTOL MYERS SQUIBB : Transgene and Bristol-Myers Squibb Announce Clinical Rese..
04/24 BRISTOL MYERS SQUIBB : Supreme Court - Argument Schedule
04/22 BRISTOL MYERS SQUIBB : BMS-986036 (Pegylated FGF21) Shows Consistent Improvement..
04/21 BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion Recommending Approval of O..
04/20 BRISTOL MYERS SQUIBB : Trademark Application for "SUPPORT AT THE SPEED OF LIFE" ..
04/20 BRISTOL MYERS SQUIBB : and Apexigen, Inc. Announce Clinical Collaboration to Eva..
04/20 BRISTOL MYERS SQUIBB : Bavarian Nordic Announces Initiation of Phase 2 Combinati..
04/18 BRISTOL MYERS SQUIBB : Myers, Nordic Bioscience To Develop Fibrosis Biomarker Te..
04/18 BRISTOL-MYERS SQUIBB CO : Blog Coverage Bristol-Myers and Nordic Announce an Agr..
More news
Sector news : Pharmaceuticals - NEC
06:13pDJNasdaq Composite Tops 6000 for First Time
02:59pDJASTRAZENECA : Lung Cancer Treatment Approved in EU
02:14pDJELI LILLY AND : Working to Cut Costs
10:17a Fresenius picks up M&A pace with Akorn, Merck KGaA deals
09:09aDJNOVARTIS : Profit Dented by Investment in New Drugs -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12:51p BIOGEN JUMPS ON Q1 RESULTS : Analysis
12:38p Nash Interest Strong Despite Latest Recruitment Delay
04/24 My 83 Stock Portfolio Review Highlighting Defensive Sectors And My Energy Sto..
04/24 INCYTE : Little Upside Left
04/24 Game Plan For The Week - Cramer's Mad Money (4/21/17)
Financials ($)
Sales 2017 19 748 M
EBIT 2017 5 201 M
Net income 2017 4 482 M
Finance 2017 393 M
Yield 2017 3,04%
P/E ratio 2017 19,93
P/E ratio 2018 18,18
EV / Sales 2017 4,45x
EV / Sales 2018 4,27x
Capitalization 88 224 M
More Financials
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 55,8 $
Spread / Average Target 4,1%
Consensus details
EPS Revisions
More Estimates Revisions
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON6.67%333 142
ROCHE HOLDING LTD.8.21%220 797
PFIZER INC.3.88%200 926
NOVARTIS AG-1.08%195 490
MERCK & CO., INC.5.55%170 359
More Results